Bleeding Disorders Treatment Market Report by Type, Drug Class, Distribution Channel, End User, and Region 2024-2032
출혈성 질환 치료 시장 규모는 2023년 150억 달러에 달했습니다. 향후 IMARC Group은 시장이 2032년까지 239억 달러에 이를 전망이며 2024년과 2032년 사이에 5.12%의 복합 연간 성장률(CAGR)을 나타낼 것으로 예측했습니다.
출혈성 질환에는 혈우병 A와 B, 폰윌브랜드병, 특발성 혈소판 감소성 자반병(ITP), 비타민 K 및 인자 II, V, VII, X, XII의 결핍이 포함됩니다. 이 질병은 혈액 응고 과정을 저해하는 질병 그룹입니다. 이 질병은 또한 상해 후에 대량과 긴 출혈을 일으킬 수 있습니다. 월경시 출혈량이 많고, 타박상이 생기기 쉽고, 비혈이 잘 나오는 가벼운 절상으로부터의 출혈이 많고, 관절로부터의 출혈이 많은 등의 증상이 있습니다. 전혈구 산정(CBC), 혈소판 응집능, 출혈 시간 등의 혈액 검사에 의해 진단됩니다. 치료에는 아드레노크롬 모노세미카르바존, 망막 출혈, 코출혈, 아미노카프로산, 아프로티닌, 철제 등의 약제가 사용됩니다. 이 약은 특정 증상을 최소화하고 환자의 연명을 도울 수 있습니다. 출혈성 질환의 치료에는 수혈, 보충 요법, 응고 인자 및 혈장 주사도 포함됩니다.
출혈성 질환 치료 시장 경향:
대중에서 출혈성 질환의 유병률 증가와 이러한 병리에 걸리기 쉬운 노년 인구 증가는 시장을 견인하는 주요 요인 중 하나입니다. 또한 출혈성 질환 치료에 경제적 지원을 제공하고 건강 관리 비용을 줄이는 건강 보험 정책의 채택이 증가하고 있는 것도 시장에 긍정적인 영향을 미치고 있습니다. 게다가 많은 국가의 행정기관들이 헌혈과 혈장제공에 대한 인식을 높이고 있습니다. 또, 헌혈 캠프를 추진하는 대처도 실시했습니다. 이와는 별도로 효과적인 대체 치료법이 이용 가능하다는 인식이 높아지고 있다는 점도 시장에 밝은 전망을 가져다줍니다. 또한 R&D(R&D) 활동과 의료 인프라 및 진단 기술의 상당한 개선은 시장에 좋은 전망을 제공할 것으로 예상됩니다.
이 보고서에서 다루는 주요 질문
- 세계의 출혈성 질환 치료 시장은 지금까지 어떻게 추이해, 향후 어떻게 추이해 갈 것인가?
- COVID-19는 세계의 출혈성 질환 치료 시장에 어떤 영향을 미쳤는가?
- 주요 지역 시장은?
- 유형별 시장 분석은?
- 약제 클래스별 시장 분석은?
- 판매 채널별 시장 분석은?
- 최종 사용자별 시장 분석은?
- 업계의 밸류체인의 다양한 단계란?
- 업계의 주요 촉진요인과 도전은 무엇인가?
- 세계의 출혈성 질환 치료 시장의 구조와 주요 기업은?
- 업계 경쟁도는?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사의 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 출혈성 질환 치료 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 분석 : 유형별
제7장 시장 분석 : 약제 클래스별
- 혈장 유래 응고 인자 농축물
- 시장 동향
- 주요 부문
- 제VIII인자
- 제IX인자
- 폰 윌 브랜드 병의 요인
- 활성화 프로트롬빈 복합체 농축물
- 시장 예측
- 재조합 응고 인자 농축물
- 데스모프레신
- 항섬유소용해제
- 피브린 실란트
- 기타
제8장 시장 분석 : 유통채널별
제9장 시장 내역 : 최종 사용자별
제10장 시장 분석 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
- 개요
- 구매자의 협상력
- 공급기업의 협상력
- 경쟁도
- 신규 참가업체의 위협
- 대체품의 위협
제14장 가격 분석
제15장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 프로파일
- AbbVie Inc
- Alnylam Pharmaceuticals Inc.
- Bayer AG
- CSL Behring(CSL Limited)
- Grifols SA
- Johnson & Johnson
- Novo Nordisk A/S
- Octapharma AG
- Pfizer Inc.
- Sanofi SA
- Takeda Pharmaceutical Company Limited
- Wellona Pharma
BJH
The global bleeding disorders treatment market size reached US$ 15.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 23.9 Billion by 2032, exhibiting a growth rate (CAGR) of 5.12% during 2024-2032.
Bleeding disorders involve hemophilia A and B, Von Willebrand disease, idiopathic thrombocytopenic purpura (ITP), and deficiencies of vitamin K and factors II, V, VII, X, and XII. They are a class of conditions that disrupt the blood clotting process in an individual. They can also lead to heavy and prolonged bleeding after an injury. They have symptoms, including heavy menstrual bleeding, easy bruising, frequent nosebleeds, excessive bleeding from minor cuts, and joint bleeding. They are diagnosed through blood tests of complete blood count (CBC), platelet aggregation, and bleeding time. Their treatment comprises medications, including adrenochrome monosemicarbazone, retinal hemorrhage, epistaxis, aminocaproic acid, aprotinin, and iron supplements. These medications can aid in minimizing specific symptoms and prolonging the life of patients. Bleeding disorders treatment also includes blood transfusion, replacement therapy, and injections of a clotting factor and plasma.
Bleeding Disorders Treatment Market Trends:
The increasing prevalence of bleeding disorders among the masses and the rising geriatric population, which is more susceptible to these medical conditions, are among the key factors driving the market around the world. Moreover, the growing adoption of health insurance policies that provide financial assistance for bleeding disorders treatment and reduce healthcare expenses is influencing the market positively. In addition, governing agencies of numerous countries are generating awareness about blood and plasma donation. They are also undertaking initiatives to promote blood donation camps. Apart from this, the increasing awareness about the availability of effective treatment alternatives is creating a positive outlook for the market. Furthermore, research and development (R&D) activities and considerable improvements in the healthcare infrastructure and diagnostic technologies are expected to provide a favorable outlook to the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global bleeding disorders treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, drug class, distribution channel and end user.
Breakup by Type:
Hemophilia A
Hemophilia B
Von Willebrand Disease
Others
Breakup by Drug Class:
Plasma-derived Coagulation Factor Concentrates
Factor VIII
Factor IX
Factor for Von Willebrand Disease
Activated Prothrombin Complex Concentrate
Recombinant Coagulation Factor Concentrates
Factor VIII
Factor for Von Willebrand Disease
Factor IX
Desmopressin
Antifibrinolytics
Fibrin Sealants
Others
Breakup by Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Stores
Breakup by End User:
Hospitals
Clinics
Academic and Research Institutes
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc, Alnylam Pharmaceuticals Inc., Bayer AG, CSL Behring (CSL Limited), Grifols S.A., Johnson & Johnson, Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Wellona Pharma.
Key Questions Answered in This Report:
- How has the global bleeding disorders treatment market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global bleeding disorders treatment market?
- What are the key regional markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the drug class?
- What is the breakup of the market based on the distribution channel?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global bleeding disorders treatment market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Bleeding Disorders Treatment Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Hemophilia A
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Hemophilia B
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Von Willebrand Disease
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Drug Class
- 7.1 Plasma-derived Coagulation Factor Concentrates
- 7.1.1 Market Trends
- 7.1.2 Key Segments
- 7.1.2.1 Factor VIII
- 7.1.2.2 Factor IX
- 7.1.2.3 Factor for Von Willebrand Disease
- 7.1.2.4 Activated Prothrombin Complex Concentrate
- 7.1.3 Market Forecast
- 7.2 Recombinant Coagulation Factor Concentrates
- 7.2.1 Market Trends
- 7.2.2 Key Segments
- 7.2.2.1 Factor VIII
- 7.2.2.2 Factor for Von Willebrand Disease
- 7.2.2.3 Factor IX
- 7.2.3 Market Forecast
- 7.3 Desmopressin
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Antifibrinolytics
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Fibrin Sealants
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 7.6 Others
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
8 Market Breakup by Distribution Channel
- 8.1 Hospital Pharmacies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Retail Pharmacies
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Online Stores
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by End User
- 9.1 Hospitals
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Clinics
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Academic and Research Institutes
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 AbbVie Inc
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Alnylam Pharmaceuticals Inc.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 Bayer AG
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 CSL Behring (CSL Limited)
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.5 Grifols S.A.
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.5.4 SWOT Analysis
- 15.3.6 Johnson & Johnson
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 Novo Nordisk A/S
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.7.4 SWOT Analysis
- 15.3.8 Octapharma AG
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 SWOT Analysis
- 15.3.9 Pfizer Inc.
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Sanofi S.A.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
- 15.3.11 Takeda Pharmaceutical Company Limited
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.11.3 Financials
- 15.3.11.4 SWOT Analysis
- 15.3.12 Wellona Pharma
- 15.3.12.1 Company Overview
- 15.3.12.2 Product Portfolio
